|
MC-4232 COMBINATION PRODUCT
 "The data from MATCHED demonstrate the unique properties of MC-4232, including its antihypertensive, hypoglycemic, and lipid lowering effects. We are now substantially closer to commercialization of a product that today has no comparable competitor – a product that offers a wide range of complimentary benefits for the growing diabetic hypertensive population." Albert D. Friesen, PhD, Medicure's President & Chief Executive Officer
Medicure's first combination product is MC-4232, a drug that combines the cardioprotective benefit of MC-1 with an ACE inhibitor, lisinopril,for the treatment of diabetic patients with hypertension. As the incidence of diabetes continues to increase so does the number of diabetic patients with hypertension. Current statistics show that approximately 75% of diabetics have hypertension, and less than 20% are chieving target blood pressure levels. Medicure developed MC-4232 to address the emerging problem of diabetes and hypertension.
Medicure recently announced positive results from the Phase II MATCHED study (MC-1 and ACE Therapeutic Combination for Hypertensive Diabetics), evaluating the effects of MC-4232 in patients with coexisting diabetes and hypertension. The Company is pleased to report that
MC-4232 met primary blood pressure and metabolic endpoints in the MATCHED study, demonstrating the products antihypertensive, hypoglycemic, and lipid lowering properties.
DIABETES / HYPERTENSION
|
Medical Problems
|
Potential Benefits of MC-4232
|
High blood pressure (hypertension)
|
Blood pressure reduction
|
High blood sugars (hyperglycemia)
|
Blood sugar/Glucose control
|
Elevated lipids
|
Lipid lowering
|
Multiple medications
|
Combo therapy in one drug
|
|
|
|
|
Management Team 
